8-K: Cabaletta Bio Presents Promising Data on rese-cel

Cabaletta Bio announced new clinical and translational data from its RESET-PV trial, showing positive activity and tolerability of rese-cel without preconditioning.

Summary

• Cabaletta Bio presented new clinical and translational data from four refractory pemphigus vulgaris (PV) patients treated with rese-cel at the lowest dose without preconditioning in the RESET-PV trial.
• Key findings include observed biologic and clinical activity after discontinuing immunomodulators, with two patients showing compelling clinical activity through six months.
• Three out of four patients remained off all immunomodulators and steroids as of the data cut-off, and complete peripheral B cell elimination was observed in three patients.
• The safety profile at the lowest dose was favorable, with one patient experiencing Grade 1 cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS).
• Based on these results, additional patients have been enrolled at a higher dose cohort, with durability data expected in the second half of 2026.
• The RESET-SLE trial, evaluating rese-cel without preconditioning in lupus patients, has fully enrolled its initial dose cohort, with initial data anticipated in the first half of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to promising clinical data and a favorable safety profile, indicating progress in the development of rese-cel.

Positives

• Observed clear biologic and clinical activity in patients after discontinuing all immunomodulators, demonstrating rese-cel's potential efficacy without preconditioning.
• Two out of four patients demonstrated compelling clinical activity through six months of follow-up.
• Three out of four patients remained off all immunomodulators and steroids as of the data cut-off, indicating sustained treatment effect.
• Complete peripheral B cell elimination was observed in three out of four patients, suggesting a mechanism of action.
• Favorable safety profile at the lowest dose, with only Grade 1 CRS in one patient and no ICANS observed.
• Enrollment of additional patients at a higher dose cohort in the RESET-PV trial, indicating confidence in the drug's potential.
• Initial dose cohort in the RESET-SLE trial is fully enrolled, with data expected soon.

Negatives

• Only two out of four patients demonstrated compelling clinical activity through six months.
• Complete peripheral B cell elimination was observed in only three out of four patients.
• One patient experienced Grade 1 cytokine release syndrome (CRS).

Risks

• The risk that signs of biologic activity or persistence may not inform long-term results.
• Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in its preclinical studies and clinical trials of rese-cel.
• The risk that results observed with similarly-designed constructs in academic publications are not indicative of results with rese-cel.
• Risks that results from one program may not translate to results for another program.
• Modifications to trial design or approach may not have the intended benefits, and further modifications may be needed.
• Risks related to clinical trial site activation, delays in enrollment, or lower than expected enrollment rates.
• Delays related to the assessment of clinical trial results.
• Unexpected safety or efficacy data observed during clinical studies.

Future Outlook

Durability data at the higher dose in the RESET-PV trial is anticipated in the second half of 2026. Initial data from the first dose cohort of the RESET-SLE trial (no preconditioning) is anticipated in the first half of 2026. Cabaletta plans to incorporate a new dose-escalation cohort into the RESET-SLE trial.

Management Comments

• Based on the safety profile observed at the lowest dose, multiple additional patients have been enrolled at a higher dose cohort in the RESET-PV trial and durability data at the higher dose is anticipated in the second half of 2026.
• The RESET-SLE trial evaluating rese-cel without preconditioning in patients with lupus, the initial dose cohort is fully enrolled with initial data at the first dose anticipated in the first half of 2026.

Industry Context

StockSavvy.ai notes that the presentation of positive clinical data, particularly demonstrating efficacy without the need for harsh preconditioning regimens, is a significant development in the gene and cell therapy space for autoimmune diseases. This approach aims to improve patient tolerability and broaden the applicability of such therapies.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data, potentially increasing the company's valuation and future prospects.
• Patients: Potential for a more tolerable and effective treatment option for pemphigus vulgaris and lupus.
• Medical Community: Provides new insights into the efficacy and safety of gene therapy without preconditioning for autoimmune diseases.

Next Steps

• Present new clinical and translational data from 4 refractory patients in the RESET-PV trial at ASGCT 2026 Annual Meeting.
• Enroll additional patients at a higher dose cohort in the RESET-PV trial.
• Anticipate durability data at the higher dose in RESET-PV in the second half of 2026.
• Anticipate initial data from the first dose cohort of the RESET-SLE trial in the first half of 2026.
• Incorporate a new dose-escalation cohort into the RESET-SLE trial.

Key Dates

Recommendation

The presented data is encouraging, showing positive clinical activity and a manageable safety profile for rese-cel without preconditioning. However, it is early-stage data from a small number of patients. Further data from higher dose cohorts and additional trials are needed to confirm efficacy and durability before a stronger recommendation can be made. The company is progressing as expected, but significant clinical and regulatory hurdles remain.

Keywords

Cabaletta Bio, rese-cel, RESET-PV trial, pemphigus vulgaris, ASGCT, gene therapy, autoimmune disease, clinical trial